Mar 27, 2026 08:16AM BioXcel Therapeutics (BTAI) Misses Q4 EPS by 58c

Mar 17, 2026 07:57AM Rodman & Renshaw Starts BioXcel Therapeutics (BTAI) at Buy, PT $17

Feb 12, 2026 07:01AM BioXcel Therapeutics advances IGALMI commercialization for at-home use

Jan 20, 2026 07:01AM BioXcel submits application to expand IGALMI use to at-home setting

Oct 17, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Oct 14, 2025 07:03AM BioXcel reports positive correlation study results for at-home agitation treatment

Sep 22, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Sep 11, 2025 10:34AM BioXcel Therapeutics (BTAI) PT Raised to $4 at Mizuho, 'Next Financing Remains Our Focus'

Aug 27, 2025 06:55AM BioXcel Therapeutics (BTAI) Halted, News Pending

Aug 18, 2025 07:00AM BioXcel receives FDA alignment for BXCL501 at-home agitation treatment

Aug 18, 2025 06:48AM BioXcel Therapeutics (BTAI) PT Raised to $10 at H.C. Wainwright

Aug 15, 2025 09:36AM BioXcel Therapeutics receives preliminary FDA feedback ahead of meeting

Aug 12, 2025 08:21AM BioXcel Therapeutics (BTAI) Misses Q2 EPS by 245c

Aug 6, 2025 07:01AM BioXcel Therapeutics publishes study on dexmedetomidine stress effects

Aug 4, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Jul 28, 2025 05:52AM BioXcel Therapeutics (BTAI) PT Lowered to $2 at Mizuho

Jul 22, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Jul 21, 2025 07:01AM BioXcel submits FDA meeting package for IGALMI outpatient expansion

Jul 3, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Jul 1, 2025 07:02AM BioXcel Therapeutics (BTAI) Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial

Jun 23, 2025 06:39AM BioXcel Therapeutics (BTAI) PT Raised to $8 at H.C. Wainwright

May 27, 2025 08:01AM BioXcel Therapeutics (BTAI) Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY Phase 3 Trial

May 12, 2025 07:01AM BioXcel Therapeutics (BTAI) Misses Q1 EPS by 129c

Mar 11, 2025 07:01AM BioXcel Therapeutics (BTAI) Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial

Mar 7, 2025 07:00AM BioXcel Therapeutics (BTAI) Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 3, 2025 03:36PM BioXcel Therapeutics (BTAI) announces direct offering of $14 million

Mar 3, 2025 01:18PM BofA Securities Reiterates Underperform Rating on BioXcel Therapeutics (BTAI), PT $4, 'still work to be done'

Mar 3, 2025 07:00AM BioXcel Therapeutics (BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

Feb 28, 2025 07:01AM BioXcel Therapeutics (BTAI) Regains Nasdaq Compliance

Feb 6, 2025 07:01AM BioXcel Therapeutics (BTAI) Announces 1:16 Reverse Share Split

Feb 5, 2025 07:00AM BioXcel Therapeutics (BTAI) Provides Clinical and Business Update

Jan 30, 2025 06:40AM BioXcel Therapeutics (BTAI) PT Lowered to $3 at H.C. Wainwright

Jan 7, 2025 07:18AM BofA Securities Downgrades BioXcel Therapeutics (BTAI) to Underperform, 'The next 12 months will be a critical inflection point'

Jan 6, 2025 06:58AM BioXcel Therapeutics (BTAI) PT Lowered to $5 at Canaccord Genuity

Nov 22, 2024 08:18AM BioXcel Therapeutics (BTAI) Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024 04:48PM BioXcel Therapeutics (BTAI) Announces Proposed Public Offering

Nov 19, 2024 07:20AM Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI)

Nov 14, 2024 07:01AM BioXcel Therapeutics (BTAI) Tops Q3 EPS by 19c

Nov 12, 2024 07:03AM BioXcel Therapeutics (BTAI) Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

Oct 21, 2024 06:55AM BioXcel Therapeutics (BTAI) PT Lowered to $5 at H.C. Wainwright

Oct 15, 2024 07:01AM BioXcel Therapeutics (BTAI) Announces U.S. DoD Grant to University of North Carolina to Fund Study of BXCL501

Sep 23, 2024 07:04AM Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI)

Sep 19, 2024 07:02AM BioXcel Therapeutics (BTAI) Announces Clinical Prioritization and Update on BXCL501

Sep 9, 2024 06:37AM Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI)

Sep 6, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Aug 30, 2024 07:32AM Canaccord Genuity Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

Aug 12, 2024 06:44AM BioXcel Therapeutics (BTAI) PT Lowered to $1 at Mizuho

Aug 7, 2024 06:48AM BioXcel Therapeutics (BTAI) PT Lowered to $7 at H.C. Wainwright

Aug 6, 2024 07:05AM BioXcel Therapeutics (BTAI) Tops Q2 EPS by 50c

Jun 25, 2024 07:00AM BioXcel Therapeutics (BTAI) Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI Sublingual Film for Agitation Associated with Bipolar Disorders